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ABSTRACT
Background: Extracellular nucleotides such as ATP and UTP are released from essentially all cells, and they
interact with cell surface P2 receptors to produce a broad range of physiological responses. P2Y12 receptor is
the major platelet receptor that mediates ADP-induced aggregation, P2Y12 receptor inhibitors such as clopido-
grel and prasugrel inhibit platelet aggregation, and thus, they are used in the treatment and prevention of coro-
nary artery disease. Recently, studies have focused on the P2Y12 receptor as a receptor for leukotriene E4
(LTE4), because this receptor is required for LTE4-mediated pulmonary inflammation. To establish the pres-
ence of P2Y12 receptor in human nasal mucosa, we investigated the expression and the localization of the
P2Y12 receptor in human nasal mucosa.
Methods: Human turbinates were obtained by turbinectomy from 12 patients with nasal obstruction refractory
to medical therapy. The expression of P2Y12 receptor was evaluated by RT-PCR, western blotting, and immu-
nohistochemical analysis.
Results: RT-PCR analysis of total RNA extracted from human nasal turbinate, primary cultured human nasal
epithelial cells and nasal vascular endothelial cells demonstrated the expression of P2Y12 receptor mRNA. A
band of approximately 55 kDa was detected in human turbinates by western blot analysis using anti-P2Y12 re-
ceptor antibody. We could not find any differences between P2Y12 receptor levels in allergic and non-allergic
nasal mucosa. An immunohistochemical study revealed that epithelial cells, submucosal glands and vascular
endothelial cells showed intense immunoreactivity for the P2Y12 receptor.
Conclusions: The results may have important clinical implications for understanding the role of P2Y12 recep-
tor in upper airway diseases such as allergic rhinitis and non-allergic rhinitis.
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INTRODUCTION
Extracellular purines (adenosine, ADP, and ATP) and
pyrimidines (UDP and UTP) regulate physiological
responses through a multi-gene family of P2 recep-
tors. P2 receptors are divided into 2 major classes:
P2X receptors, which are nonselective cation chan-
nels and P2Y receptors, which are members of the G
protein-coupled receptor (GPCR) superfamily.1 P2Y12
receptor is the major platelet receptor that mediates
ADP-induced aggregation,2 and P2Y12 inhibitors such
as clopidogrel and prasugrel are used in the treat-
ment and prevention of coronary artery diseases.3 Re-
cently, the P2Y12 receptor has been studied as the re-
ceptor for leukotriene E4,4 because it was shown that
not only ADP but also leukotriene E4 (LTE4) activates
P2Y12 receptor at nanomolar concentrations.5 Admini-
stration of exogenous LTE4 into human airways
causes airway obstruction and mucosal eosinophilia
in patients with asthma,6-8 and purinergic P2Y12 re-
ceptor is required for LTE4-mediated pulmonary in-
flammation.9,10 Therefore, to understand the role of
LTE4 in allergic airway diseases, information about
the localization of P2Y12 receptor is very important.
However, only a limited number of studies have been
performed in this field. In the present study, western
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Table　1　Demographic characteristics of allergic and non-
allergic patients
Allergic
rhinitis
N = 6
Non-allergic 
patients
N = 6
Sex (male/female) 2/4 3/3
Age (years)   31 (19-58)  39 (28-55)
Specifi c IgE to house dust 
mite (d1) (kU/L)
 2.7 (1.0-13) <0.35
Total IgE (kU/L)  210 (10-387) 110 (10-185)
Blood eosinophils (cells/μL)  370 (70-690) 135 (55-240)
Current nasal symptoms 
(number of patients)
Nasal obstruction 6 (all patients) 6 (all patients)
Sneezing 4 0
Rhinorrhea 3 2
Data expressed as median values and range (in parentheses).
blotting, immunohistochemistry and RT-PCR analysis
for P2Y12 receptor were performed to confirm the ex-
pression of P2Y12 receptor mRNA and protein in hu-
man allergic and non-allergic nasal mucosa.
METHODS
TISSUE PREPARATION
Human inferior turbinates were obtained after tur-
binectomy from 12 patients with nasal obstruction
that was refractory to medical therapy. Informed con-
sent was obtained from all patients, and this study
was approved by the ethics committee of Sapporo
Medical University (approval number: 24-14). All pa-
tients were nonsmokers, of which 6 had perennial al-
lergy to mites, as diagnosed through questionnaires
and the CAP test (Pharmacia, Uppsala, Sweden). The
remaining 6 patients, who had concomitant septo-
plasty because of symptomatic nasal septal deviation,
with a negative CAP test for major inhaled allergens
such as mites, birch, grass, mugwort, and Japanese
cedar, were included in the non-allergic rhinitis group
as control. All medications, including antibiotics,
were prohibited for at least 3 weeks prior to the
study. The demographic and clinical characteristics
of the patients are summarized in Table 1. The nasal
mucosal specimens were (1) immediately frozen in
liquid nitrogen and stored at -70℃ for RNA and pro-
tein extraction for RT-PCR and western blotting, re-
spectively, (2) placed into cold transfer medium
(RPMI 1640 medium) for epithelial cell and vascular
endothelial cell culture, and (3) fixed in 10% formalin
for immunohistochemistry.
HUMAN NASAL VASCULAR AND EPITHELIAL
CELL CULTURE
Vascular Endothelial Cell Culture
Human nasal vascular endothelial cells (HNVECs)
were isolated from nasal inferior turbinates according
to a previously described protocol with minor modifi-
cations.11 The nasal specimen was cut into 2-mm2 sec-
tions and enzymatically digested using 0.2% collage-
nase type IV solution (Sigma, St. Louis, MO, USA) for
5 min at 37℃, washed with MCBD 131 medium
(Sigma) containing 5% FCS and 2 ngmL vascular en-
dothelial growth factor (Invitrogen, Carlsbad, CA,
USA), and placed in collagen type-I-coated 6-well cul-
ture plates (Sumitomo Bakelite, Osaka, Japan). After
24 h, the medium and the tissue pieces were dis-
carded, and the culture plate was washed twice to re-
move floating cells. Fresh MCBD 131 medium
(Sigma) containing 5% FCS and 2 ngmL vascular en-
dothelial growth factor was added, and the cells were
cultured in a 5% carbon dioxide humidified atmos-
phere at 37℃. The culture medium was changed at
day 1 and every 2 days thereafter. Monolayer cell
confluence was achieved after 7-10 days of culture.
Morphologic observations using a phase contrast mi-
croscope showed that HNVECs consisted primarily
of vascular endothelial cells. More than 95% of the
HNVECs showed positive reactions for anti-human
CD31 antibody (Dako, Denmark). HNECs grown to
80% confluency were used for RT-PCR analysis and
western blotting.
Epithelial Cell Culture
Human nasal epithelial cells (HNECs) were isolated
from human nasal mucosa specimens according to a
previously described protocol.12 Nasal specimens
were rinsed 2-3 times with Ham’s F-12 medium
(Sigma) supplemented with antibiotics and incubated
in 0.1% protease type XIV in Ham’s F-12 medium for
16 h at 4℃. After incubation 10% fetal bovine serum
was added to neutralize protease activity and epithe-
lial cells were detached by gentle agitation. Cell sus-
pensions were filtered through a 60-mesh cell disso-
ciation sieve (Sigma) and centrifuged at 500×g for 10
min at room temperature. The cell pellet was then re-
suspended in hormonally defined Ham’s F-12 culture
medium (Ham’s HD). Cell suspensions were plated
onto collagen type-I-coated 6-well culture plates (Su-
mitomo Bakelite) in Ham’s HD medium and cultured
in a 5% carbon dioxide humidified atmosphere at 37
℃. The culture medium was changed at day 1 and
every 2 days thereafter. Monolayer cell confluence
was achieved after 6-8 days of culture. Morphologic
observations using a phase contrast microscope
showed that the HNECs consisted primarily of epi-
thelial cells. More than 95% of the HNECs showed
positive reactions for anti-human cytokeratin anti-
body (Dako). HNECs grown to 80% confluency were
used for RT-PCR analysis.
RT-PCR Analysis
Total RNA from nasal mucosa was extracted using
TRIzol reagent (Invitrogen). Some of the RNA sam-
ples (1 μgμL) were treated with DNase I (10 UμL)
P2Y12 Receptor in Nasal Mucosa
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Fig.　1　Detection of P2Y12 receptor mRNA by RT-PCR af-
ter 40 cycles of amplifi cation from primary cultured human 
nasal epithelial cells, primary cultured human vascular endo-
thelial cells, and inferior turbinate. RNA was extracted, and 
RT-PCR was performed using P2Y12 receptor primers, gen-
erating a 432-bp fragment. Lane M: 100 bp ladder. Lane 1: 
PCR products from total RNA of primary cultured human na-
sal epithelial cells. Lane 2: PCR products from total RNA of 
primary cultured human nasal vascular endothelial cells. 
Lane 3: PCR products from total RNA of human inferior tur-
binate.
M 1 2 3for 30 min to avoid DNA contamination following the
second RNA extraction. RT-PCR was carried out us-
ing a commercial One Step RNA PCR Kit (Takara
Biomedicals, Tokyo, Japan). RNA (50 ng) was
reverse-transcribed into cDNA by incubating with 5
U AMV Reverse Transcriptase XL at 50℃ for 30 min.
After denaturation at 94℃ for 2 min, cDNA was am-
plified by 40 cycles of PCR (94℃ for 30 s, 60℃ for 30
s, and 72℃ for 1 min) with 5 U of AMV-Optimized
Taq DNA polymerase to amplify the genes of the
P2Y12 receptor. For P2Y12 receptor, the forward
primer: 5’-CTAAGATTCTCTCTGTTGTCATCTG-3’
and the reverse primer: 5’-ACAGAGTGCTCTCTTTC
ACATAG-3’ were used to generate a 432-bp frag-
ment.13 PCR products were analyzed by agarose elec-
trophoresis in a 1.5% gel and visualized by ethidium
bromide staining.
Western Blot Analysis
For the western blot of P2Y12 receptor, rabbit anti-
human P2Y12 receptor polyclonal antibody (product
number P4871, Sigma) was used at 4 μgmL.
Nasal mucosa and primary cultured nasal cells
were homogenized in T-PER Tissue Protein Extrac-
tion Reagent (Thermo Fisher Scientific, Waltham,
MA, USA), supplemented with a protease inhibitor
cocktail (Sigma). The protein extracts were purified
using PAGEprep Advance Kit (Thermo Fisher Scien-
tific), and the protein concentration in the homogen-
ates was determined using a BCA Protein Assay Kit
(Thermo Fisher Scientific). Protein extracts (20 μg
protein each) were separated on a 4-12% sodium do-
decyl sulfphate (SDS)-polyacrylamide gel and blotted
onto a polyvinylidene difluoride (PVDF) membrane
(Invitrogen). Membranes were then blocked and
probed with rabbit anti-human P2Y12 receptor poly-
clonal antibody (4 μgmL; Sigma) or rabbit anti-
human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) polyclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) as an internal control.
The bands were visualized using a WesternBreeze
chromogenic western blot immunodetection kit (Invi-
trogen). The ratio of the expression of P2Y12 receptor
protein to GAPDH protein was evaluated by densi-
tometry.
Immunohistochemistry
For immunohistochemistry of the P2Y12 receptor,
rabbit anti-human P2Y12 receptor polyclonal antibody
(product number P4871, Sigma) was used at 20 μg
mL. Deparaffinized sections were initially incubated
with 3% H2O2 in methanol for 30 min to quench the
endogenous peroxidase activity. After microwave
treatment (10 min at 500 W in citrate buffer), the sec-
tions were incubated in the blocking solution (10%
normal goat serum in PBS) for 30 min before incuba-
tion with the primary antibody. Then, the sections
were incubated with anti-P2Y12 receptor polyclonal
antibody overnight at 4℃, washed, and incubated for
30 min with Alexa Fluor 488-labelled goat anti-rabbit
IgG (diluted 1 : 100; Molecular Probes, OR, USA).
Sections were mounted with SlowFade antifade kits
(Molecular Probes) and examined under an Olympus
BX51 microscope with a DP70 CCD camera (Olym-
pus Optical, Tokyo, Japan). All images were proc-
essed with DP Controller and DP Manager software
(Olympus Optical) for image analysis. Negative con-
trols were obtained by replacing primary antibodies
with rabbit immunoglobulin fraction (Dako).
Statistical Analysis
The protein levels of P2Y12 receptor and GAPDH
evaluated by western blot analysis were determined
in duplicate, and data are presented as mean ± stan-
dard deviation. The non-parametric Mann-Whitney U
test was used to determine the differences between
perennial allergic rhinitis and non-allergic rhinitis.
Values with P0.05 were considered statistically sig-
nificant.
RESULTS
RT-PCR ANALYSIS
The results of RT-PCR for 40 cycles using total RNA
extracted from human nasal mucosa (Fig. 1, lane 1),
Shirasaki H et al.
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Fig.　2　Representative western blots for the P2Y12 recep-
tor protein in human nasal mucosa (lane 1: primary cultured 
human nasal epithelial cells, lane 2: primary cultured human 
nasal vascular endothelial cells, lane 3; human inferior turbi-
nate). The antibody recognized a single protein of 55 kDa, 
referred to as the P2Y12 receptor.
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Fig.　3　A: Western blots showing P2Y12 receptor protein 
level in allergic nasal mucosa (lanes 1-6) and non-allergic 
nasal mucosa (lanes 7-12). B: Densitometric analysis of the 
relative protein level of the P2Y12 receptor is shown. The 
data are expressed as mean ± SD and normalized to GAP-
DH.
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Fig.　4　Immunofl uorescence staining for P2Y12 receptor in 
human nasal mucosa. Inferior turbinates were stained with 
anti-human P2Y12 receptor antibody (A) or normal rabbit im-
munoglobulin (B). P2Y12 receptor immunoreactivity was ob-
served mainly on vascular endothelial cells (ve), epithelium 
(ep) and submucosal glands (g). Scale bar = 200 μm.
primary cultured human nasal vascular endothelial
cells (Fig. 1, lane 2), and primary cultured human na-
sal epithelial cells (Fig. 1, lane 3), revealed the ex-
pression of P2Y12 receptor mRNA. These results sug-
gested the presence of P2Y12 receptor mRNA in hu-
man nasal epithelial cells and vascular endothelial
cells.
WESTERN BLOTTING
In order to determine the protein size of P2Y12 recep-
tor in human nasal mucosa, P2Y12 receptor expres-
sion was confirmed by western blot analysis. As
shown in Figure 2, the expression of a single band for
P2Y12 receptor protein in human nasal mucosa (lane
1: primary cultured human nasal epithelial cells, lane
2: primary cultured human nasal vascular endothelial
cells, lane 3; human inferior turbinate) could be dem-
onstrated.
Densitometric quantification of the bands was per-
formed to evaluate the expression levels of P2Y12 re-
ceptor (the ratio of P2Y12 receptorGAPDH) in aller-
gic and non-allergic nasal mucosa (Fig. 3). The differ-
ence in P2Y12 receptor expression between allergic
and non-allergic nasal mucosa was not significant (al-
lergic rhinitis: 0.52 ± 0.11, non-allergic patients: 0.43 ±
0.12, P = 0.26; Fig. 3B).
IMMUNOHISTOCHEMISTRY
The distribution of P2Y12 receptor in the nasal mu-
cosa was examined by immunohistochemical analy-
sis. As shown in Figure 4A, significant immunoreac-
tivity for the P2Y12 receptor was detected in epithelial
cells, vascular endothelial cells, and submucosal
glands. The specificity of the staining was also con-
firmed by the absence of labeling with normal rabbit
immunoglobulin (Fig. 4B).
DISCUSSION
This is the first study to clarify the expression and the
localization of the P2Y12 receptor in human nasal mu-
cosa. Although P2Y12 receptor inhibitors such as
clopidogrel and prasugrel have been used clinically,
P2Y12 receptor has mostly been studied in cardiovas-
cular and cerebrovascular disease.3 In northern blots
of human tissue extracts, Hollopeter et al. found
P2Y12 receptor mRNA in platelets and the brain
only.14 Zhang et al. observed strong expression of
P2Y12 Receptor in Nasal Mucosa
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P2Y12 receptor in the platelets and in all brain regions
(plus spinal cord) tested, weak expression in lungs,
pituitary, and adrenal gland, but no expression in any
other tissues.15 The finding of western blot analysis
showed that the molecular mass of the nasal P2Y12
receptor is approximately 55 kDa, which is similar to
that of P2Y12 receptor found in human platelets and
the internal mammary artery,16 although their ex-
pected size is 40 kDa. Such a difference could be be-
cause the nasal P2Y12 receptor has post-transc-
riptional modifications, such as glycosylation and
lipoylation.17 In addition, we could not detect any dif-
ferences in the P2Y12 receptor expression between al-
lergic and non-allergic nasal mucosae obtained from
the non-smoking patients. Our recent experiments
using primary cultured nasal epithelial cells revealed
no significant difference of P2Y12 receptor level in be-
tween allergic and non-allergic epithelial cells (data
not shown). To the best of our knowledge, only one
study has previously identified an agent that either
upregulates or downregulates P2Y12 receptor expres-
sion. The study showed the effect of nicotine on
P2Y12 receptor expression in four 4 cell lines.18 It is
likely that long-term exposure to nicotine is neces-
sary for P2Y12 receptor up-regulation, because plate-
lets from smokers have higher levels of P2Y12 recep-
tor than platelets from non-smokers.18 From these
observations, it is possible that smoking accelerates
LTE4-induced airway inflammation via up-regulation
of P2Y12 receptor. Recently, it was shown that 5
single-nucleotide polymorphisms (SNPs) in the P2Y12
gene are associated with lung function in a large
family-based asthma cohort.19 Thus, the inhibitors of
P2Y12 receptor could lead to new therapeutic targets
for asthma and allergic rhinitis.
Our present immunohistochemical studies, west-
ern blotting, and RT-PCR analysis clearly show the
expression of the P2Y12 receptor on not only nasal
vascular endothelial cells but also nasal epithelial
cells at the mRNA and protein level. With respect to
the expression of P2Y12 receptor on nasal epithelial
cells, a previous study identified P2Y12 receptor
mRNA in human primary cultured nasal epithelial
cells by RT-PCR analysis.13 The extracellular purines
(adenosine, ADP, and ATP) and pyrimidines (UDP
and UTP) regulate various physiological responses
via cell surface receptors namely, purinoreceptors,
and they exert autocrine or paracrine effects on
ion transport,20 fluid transport,21 ciliary beat fre-
quency,20,22 and mucin secretion.23 Thus, the puri-
noreceptors in nasal epithelial cells may play an im-
portant role in nasal secretion under inflammatory
conditions. Until recently, there were only a few re-
ports on the expression of subtypes of P2 receptors in
nasal epithelial cells.13,24 Further, it is still unclear
whether the P2Y12 receptor in nasal epithelial cells is
functionally active. Recently, we found LTE4 caused
the secretion of MUC5AC mucin from lung epithelial
NCI-H292 cells via activation of P2Y12 receptor (un-
published data), suggesting therapeutic potential of
P2Y12 receptor antagonists on allergic mucous secre-
tion. In order to clarify the roles of P2Y12 receptor in
nasal epithelial cells, a study using cultured nasal
mucosa-derived epithelial cells is now in progress at
our laboratory.
In this study, we also found expression of the
P2Y12 receptor on vascular endothelial cells. P2Y12
receptor was originally identified in platelets.14 Sub-
sequent studies have demonstrated that the recep-
tor is expressed in vascular endothelial cells.18,25 In
endothelial cells, ATP generally causes an increase in
[Ca2+] via the activation of P2Y receptors, which are
coupled to phospholipase C and inositol 1,4,5-
triphosphate-induced Ca2+ mobilization.1 ATP in-
creases vascular permeability,26,27 vasodilator produc-
tion such as endothelial nitric oxide synthase
(eNOS)28 and expression of intercellular adhesion
molecule-1 (ICAM-1)29 in human vascular endothelial
cells through a Ca2+-dependent pathway. These may
be important physiological roles for P2Y receptors in
nasal endothelial cells.
The present study showed the significant expres-
sion of P2Y12 receptor expression in the nasal submu-
cosal glands. With regard to the P2Y receptor sub-
types in human submucosal glands, only the pres-
ence of P2Y2 receptor and P2Y4 receptor in a cell line
(MM39) of human tracheal gland cells has been re-
ported by using RT-PCR.30 To date, no detailed study
has reported the existence or the roles of the P2Y12
receptor in airway submucosal glands. Activation of
the P2Y receptors on nasal glands may cause mucus
secretion, because P2Y-receptor agonist 2-methylthio-
ATP evoked an increase in K+ and Cl− conductance in
avian nasal gland cells.31
In conclusion, this study provides important infor-
mation about the localization of the P2Y12 receptor on
the nasal mucosa. The present findings should be of
considerable interest for understanding the potential
roles of P2Y12 receptor in upper airway diseases such
as allergic rhinitis and non-allergic rhinitis.
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